Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved...
—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company...
--Chief Medical Officer Dr. Barbara Klencke, to be joined by leading myelofibrosis experts Drs. Aaron Gerds, Stephen Oh and Srdan Verstovsek-- SAN MATEO, Calif., June 14, 2021 /CNW/ - Sierra...
